| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2017: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Outline of Final Research Achievements |
Cancer cells acquire radioresistance under hypoxic microenvironments. In order to elucidate biological mechanism behind it and establish a new therapeutic strategy, we focus on novel genes that may mediate “cellular adaptive response to hypoxia” and “cellular antioxidative activity”. We found that the expression of the novel gene was induced by a mechanism dependent of HIF-1β but not of either HIF-1α or HIF-2α. Moreover, we found that its gene product was secreted extracellularly. It was also confirmed that the gene product significantly reduced the number of DNA double-strand breaks after irradiation and induces radioresistance of cancer cells in a autocrine fashion. We further found the possibility of establishing a system for monitoring the amount of tumor hypoxia using the blood concentration of the gene product.
|
